2 years ago
HIMS
AnalystsJack WallaceJack Wallace's Stock Forecasts
AnalystsJack Wallace
Analyst Ranking
Top 26%
#1246 out of 4873 analysts
Average Return
+5.64%
Win Rate
52%12 out of 23
Risk vs Reward
Poor
Good
Jack Wallace's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Hims & Hers Health IncHIMS | +211.91% | $13.43 | $41.89 | 2024-02-26 - 2025-02-26 | Strong Buy |
Hims & Hers Health IncHIMS | +98.62% | $5.06 | $10.05 | 2022-04-13 - 2023-04-13 | Strong Buy |
Phreesia IncPHR | +60.68% | $20.32 | $32.65 | 2022-06-02 - 2023-06-02 | Strong Buy |
Nextgen Healthcare IncNXGN | +52.87% | $15.66 | $23.94 | 2023-05-22 - 2023-11-08 | Strong Buy |
Nextgen Healthcare IncNXGN | +48.14% | $16.16 | $23.94 | 2023-07-24 - 2023-11-08 | Strong Buy |
Jack Wallace Analyst Color
Get additional color on Jack Wallace's coverage of popular stocks
2 years ago
PHR
Jack Wallace's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Veeva Systems IncVEEV | 3 | Strong Buy | $249.00 | +4.48% | Maintains | 7 months ago |
Ww International IncWW | 3 | Strong Buy | $6.00 | +1,233.33% | Maintains | 9 months ago |
R1 Rcm IncRCM | 4 | Strong Buy | $15.00 | N/A | Maintains | a year ago |
Hims & Hers Health IncHIMS | 4 | Strong Buy | $17.00 | N/A | Maintains | a year ago |
Health Catalyst IncHCAT | 2 | Strong Buy | $14.00 | N/A | Upgrades | a year ago |
Iqvia Holdings IncIQV | 1 | Strong Buy | $220.00 | N/A | Maintains | 2 years ago |
Nextgen Healthcare IncNXGN | 3 | Strong Buy | $22.00 | N/A | Reiterates | 2 years ago |
Phreesia IncPHR | 3 | Strong Buy | $40.00 | N/A | Maintains | 2 years ago |
American Well CorpAMWL | 1 | Strong Buy | $5.00 | N/A | Reiterates | 2 years ago |
Premier IncPINC | 1 | Hold | N/A | N/A | Initiates Coverage On | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.